Figure 5
From: EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
Effect of the IGF1R inhibitor linsitinib on ERK phosphorylation and cell proliferation. (A) Immunoblotting analysis of phosphorylated ERK (p-ERK), ERK and ACTB levels in Hep3B and LR7.5- 3B cells that had been treated with linsitinib for 4 h. (B,C) Cell proliferation was analyzed by Cell Counting Kit 8 (CCK-8) assays in Hep3B (3B) (B) and LR7.5-3B (LR) (C) cells that had been treated with or without 0.1 μM linsitinib at the indicated times (n = 4 per treatment). Representative results are shown. (D) Immunoblotting analysis of phosphorylated ERK (p-ERK), ERK and ACTB levels in Hep3B and LR7.5-3B cells that had been treated with or without 3 μM lenvatinib, alone or combined with the indicated concentration of linsitinib for 4 h. (E,F) Cell proliferation was analyzed by Cell Counting Kit 8 (CCK-8) assay in Hep3B (3B) (E) and LR7.5-3B (LR) (F) cells treated with or without 3 μM lenvatinib, alone or combined with 0.1 µM linsitinib, at the indicated times (n = 4 per treatment). The intensity with the internal control were indicated. Two independent experiments were performed, and representative results are shown. *p < 0.05.
